Medicis reiterated at outperform by RBC

RBC Capital Markets analyst Ken Trbovich reiterated Medicis Pharmaceutical Corp. at outperform, above average risk, after management provided unusual visibility into its pipeline, expecting possible approval of Perlane in the fourth quarter and additional product contributing in 2007. Medicis' launch of the facial filler, Perlane, will off-set potential weakness in the company's filler business when Allergan launches its Juvederm line. Shares of the Scottsdale, Ariz.-based pharmaceutical company were up 7 cents, or 0.26%, at $27.24, on volume of 1,703,500 shares versus the three-month running average of 1,174,910 shares. (NYSE: MRX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.